Table 3.
Univariate and multivariate analyses of prognostic factors for progression-free survival
| Factors |
Univariate
|
Multivariate
|
||
|
HR (95%CI)
|
P value
|
HR (95%CI)
|
P value
|
|
| Age (≥ 60 vs < 60), years | 0.83 (0.62-1.12) | 0.222 | ||
| Sex (male vs female) | 1.01 (0.75-1.35) | 0.954 | ||
| Drinking history (yes vs no) | 0.97 (0.71-1.33) | 0.866 | ||
| Smoking history (yes vs no) | 0.96 (0.70-1.33) | 0.818 | ||
| Site (stomach vs gastric and esophageal binding) | 1.14 (0.85-1.53) | 0.388 | ||
| ECOG (0 vs 1) | 1.86 (1.36-2.54) | < 0.001a | 1.58 (1.14-2.20) | 0.006a |
| Histological (others vs adenocarcinoma) | 0.94 (0.68-1.31) | 0.732 | ||
| TyG (low vs high) | 0.58 (0.43-0.79) | < 0.001a | 0.66 (0.48-0.90) | 0.010a |
| CEA (< 3 vs ≥ 3), ng/mL | 1.27 (0.91-1.76) | 0.159 | ||
| AFP (≥ 15 vs < 15), ng/mL | 0.79 (0.50-1.23) | 0.298 | ||
| CA-199 (< 37 vs ≥ 37), ng/mL | 1.22 (0.91-1.64) | 0.188 | ||
| Liver metastasis (yes vs no) | 0.89 (0.65-1.21) | 0.459 | ||
| Peritoneal metastasis (no vs yes) | 1.02 (0.71-1.49) | 0.899 | ||
| EBV status (infect vs no-infect) | 0.82 (0.55-1.23) | 0.341 | ||
| PD-L1 expression (CPS < 5 vs CPS ≥ 5) | 0.27 (0.18-0.40) | < 0.001a | 0.37 (0.25-0.56) | < 0.001a |
| MMR status (pMMR vs dMMR) | 2.61 (0.97-7.03) | 0.058 | ||
| BMI (< 25 vs ≥ 25), kg/m2 | 0.55 (0.37-0.82) | 0.003a | 0.56 (0.38-0.84) | 0.005a |
a
P < 0.05.
HR: Hazard ratio; CI: Confidence interval; ECOG: Eastern Cooperative Oncology Group; TyG: Triglyceride glucose; CEA: Carcinoembryonic-antigen; AFP: Alpha-fetoprotein: CA-199: Carbohydrate antigen 199; EBV: Epstein-Barr virus; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair; BMI: Body mass index.